| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
B-Crystallin immunolocalization yields new insights into inclusion body myositis
From the Department of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, MN.
Address correspondence and reprint requests to Dr. A.G. Engel, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
OBJECTIVE: To study the expression of the small heat shock protein, 
B-crystallin (BC), in inclusion body myositis (IBM).
BACKGROUND: In humans, BC is constitutively expressed in the eye lens, muscle, and heart, but not in lymphoid tissues. Induced expression of BC occurs under metabolic stress, in virus-infected lymphocytes, and in degenerative brain lesions, including neurofibrillary tangles and senile plaques in AD. The previously reported pathologic similarities between AD and IBM prompted us to study BC expression in IBM.
METHODS: Immunolocalization of BC in muscle of 11 patients with IBM, 50 patients with other muscle diseases, and 4 controls; and quantitative analysis of the frequency of fibers with 1) increased BC expression in IBM and polymyositis and 2) structural abnormality (vacuolated, non-necrotic and invaded by mononuclear cells, Congo red–positive, SMI-31 positive, and ubiquitin positive) in IBM.
RESULTS: We detected enhanced expression of BC not only in all structurally abnormal IBM fibers, but also, and with severalfold higher frequency, in IBM fibers without significant structural abnormality (X fibers) (p values in paired t-tests < 0.001). We also found enhanced BC in abnormal fibers in other diseases; X fibers, however, were extremely sparse or absent, except in two atypical cases of polymyositis refractory to immunotherapy.
CONCLUSION: That the X fibers are much more frequent than the structurally abnormal fibers in IBM points to a pathogenic stressor acting upstream to the development of structural abnormalities. The identification of this stressor is now of paramount importance for deciphering the enigma of IBM.
Key words: B-crystallin—Inclusion body myositis—Immunolocalization—T-cell response—Myopathies.
This article has been cited by other articles:
|
|
 |
|
  A A Amato and R J Barohn Inclusion body myositis: old and new concepts J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1186 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Greenberg How citation distortions create unfounded authority: analysis of a citation network BMJ, July 23, 2009; 339(jul20_3): b2680 - b2680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Dalakas, G. Rakocevic, J. Schmidt, M. Salajegheh, B. McElroy, M. O. Harris-Love, J. A. Shrader, E. W. Levy, J. Dambrosia, R. L. Kampen, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis Brain, June 1, 2009; 132(6): 1536 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kitazawa, V. Vasilevko, D. H. Cribbs, and F. M. LaFerla Immunization with Amyloid-{beta} Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model J. Neurosci., May 13, 2009; 29(19): 6132 - 6141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schmidt, K. Barthel, A. Wrede, M. Salajegheh, M. Bahr, and M. C. Dalakas Interrelation of inflammation and APP in sIBM: IL-1{beta} induces accumulation of {beta}-amyloid in skeletal muscle Brain, May 1, 2008; 131(5): 1228 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonte, D. R. Kipp, J. Yerg III, D. Merin, M. Forrestal, E. Wagner, C. M. Roberts, and C. D. Link Suppression of in Vivo -Amyloid Peptide Toxicity by Overexpression of the HSP-16.2 Small Chaperone Protein J. Biol. Chem., January 11, 2008; 283(2): 784 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Greenberg Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications Neurology, November 20, 2007; 69(21): 2008 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Askanas and W. K. Engel Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Macario and E. C. de Macario Sick Chaperones, Cellular Stress, and Disease N. Engl. J. Med., October 6, 2005; 353(14): 1489 - 1501. [Full Text] [PDF]
|
|
|
|
|
|
S. Nakano, A. Shinde, H. Ito, H. Ito, and H. Kusaka Messenger RNA degradation may be inhibited in sporadic inclusion body myositis Neurology, August 9, 2005; 65(3): 420 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakano, A. Shinde, H. Ito, H. Ito, and H. Kusaka MAP kinase phosphatase-1 is induced in abnormal fibers in inclusion body myositis Neurology, August 12, 2003; 61(3): 322 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M C DALAKAS Progress in inflammatory myopathies: good but not good enough J. Neurol. Neurosurg. Psychiatry, May 1, 2001; 70(5): 569 - 573. [Full Text] [PDF]
|
|
|
|
|
|
S. Nakano, A. Shinde, S. Kawashima, S. Nakamura, I. Akiguchi, and J. Kimura Inclusion body myositis: Expression of extracellular signal-regulated kinase and its substrate Neurology, January 9, 2001; 56(1): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Amemiya, R. P. Granger, and M. C. Dalakas Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: Studies in repeated muscle biopsies Brain, October 1, 2000; 123(10): 2030 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Karpati and R. Hohlfeld Biologically stressed muscle fibers in sporadic IBM: A clue for the enigmatic etiology? Neurology, March 14, 2000; 54(5): 1020 - 1021. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
